What are the adverse reactions of Etrasimod?

Etrasimod (Etrasimod), as an S1P receptor modulator, has demonstrated therapeutic efficacy and safety in the treatment of ulcerative colitis. However, there are still some side effects that must be paid attention to in clinical application, especially adverse reactions in cardiovascular, immune system and liver function related to its mechanism of action. Overall, most side effects were mild to moderate and could be effectively managed with monitoring and dose adjustment.

Adverse reactions in the cardiovascular system are mainly manifested as mild bradycardia, which is the result of the internalization of S1P1 receptors on autonomic nervous regulation. It is especially noticeable within 24 hours after the first dose. Therefore, it is recommended that patients should be under clinical observation when taking the drug for the first time, especially those with previous arrhythmias or patients who are taking beta-blockers. Compared with earlier S1P drugs, itramod does not act on S1P3 and the risk of cardiac side effects has been significantly reduced.

In terms of the immune system, itrimod can cause reversible lymphopenia because the drug blocksT cell migration from lymph nodes to the blood. Although this effect helps reduce lesion inflammation, it may lead to a decrease in the patient's resistance to viral or bacterial infections during continued medication. Clinically, patients' white blood cell counts need to be closely monitored to assess their risk of infection, especially during influenza season or when exposed to infectious environments.

Digestive system-related side effects have also been reported, such as diarrhea, nausea, decreased appetite, and mild abdominal pain. These reactions usually appear early in the medication, are short-lived, and usually do not affect treatment compliance. Some patients may also experience mild elevations in transaminases, suggesting the need for regular monitoring of liver function, especially when combined with other hepatotoxic drugs.

A few patients reported non-specific symptoms such as headache, insomnia, fatigue, etc. Most of these side effects are transient and do not affect long-term medication decisions. No significant increase in tumor incidence or serious neurological adverse events has been observed with istrimod, which is its greater advantage than traditional immunosuppressants.

Reference materials:https://www.drugs.com/mtm/etrasimod.html